Selank is a lab-made peptide — a short chain of amino acids — studied mainly for one thing: calming anxiety. Russian scientists built it from tuftsin, a tiny natural peptide your immune system uses as a signal, and added a small tail to make it last longer. The result is an anxiolytic (an anti-anxiety compound) that is an approved medicine in Russia and a research compound almost everywhere else.
In plain terms: it takes a natural immune signal, stabilises it, and turns it into a calm-without-knock-out molecule.
What it is
Selank is a heptapeptide — seven amino acids (Thr-Lys-Pro-Arg-Pro-Gly-Pro). The first four (Thr-Lys-Pro-Arg) are tuftsin, a natural four-amino-acid peptide first described in 1970 as an immune-system "eat this" signal that helps white blood cells engulf invaders1. Tuftsin on its own is fragile — it is broken down in seconds. So, exactly as with Semax, the chemists bolted on a Pro-Gly-Pro tail: a bumper that shields the peptide from the enzymes that would otherwise destroy it.
Here is the pharmacology at a glance:
| Property | Selank |
|---|---|
| Type | Synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) |
| Parent molecule | Tuftsin (Thr-Lys-Pro-Arg), plus a Pro-Gly-Pro stabiliser tail |
| Proposed action | Modulates GABA signalling; touches serotonin and enkephalins |
| Studied effect | Anxiolytic (anti-anxiety), reported without sedation |
| Typical research route | Intranasal (nose drops / spray) |
| Plasma half-life | Minutes (short; longer than tuftsin alone) |
| Regulatory status | Approved medicine in Russia; not FDA-approved (research compound) |
How it's thought to work
The headline mechanism is GABA — the brain's main "slow down and calm" chemical. In a rat study, Selank changed the activity of several genes involved in GABAergic neurotransmission (the GABA signalling system), which is a plausible route to an anti-anxiety effect3. Unlike a benzodiazepine, it is not thought to jam itself into the benzodiazepine site on the receptor; the effect looks more indirect.
Selank is also linked to two other systems. It appears to influence serotonin (a mood chemical), and it is reported to slow the breakdown of the body's own enkephalins — natural molecules involved in stress, pain, and mood regulation. In a rat model of chronic stress, Selank boosted the anti-anxiety effect of diazepam (Valium) beyond what diazepam did alone, hinting the two work through complementary paths4.
In plain terms: in animals it turns up the brain's calming GABA system and supports the mood chemicals around it — apparently without the heavy sedation benzodiazepines bring. As always, flag the level: these are animal and cell findings.
How long it lasts
Like Semax, Selank clears the blood in minutes — its plasma half-life is short because peptides are broken down quickly, though the Pro-Gly-Pro tail makes it last longer than raw tuftsin (which survives only seconds). It is studied as an intranasal peptide, and its behavioural effects appear to outlast the brief time it spends in the bloodstream.
In plain terms: gone from the blood fast, but the calming effect it triggers lasts longer than the molecule does.
What the studies actually found
Selank's evidence runs from its 1970s tuftsin roots to modern Russian anxiety trials. Here it is in order, with the model each used:
| Study | Model | Key result | Year |
|---|---|---|---|
| Najjar & Nishioka1 | Biochemistry (tuftsin) | Described tuftsin, the natural immune peptide Selank is built from | 1970 |
| Zozulia & Neznamov et al.2 | Human (anxiety, small) | In generalized anxiety disorder and neurasthenia, Selank matched the anti-anxiety effect of a benzodiazepine, with added anti-fatigue effect and no sedation | 2008 |
| Volkova et al.3 | Rat (brain) | Changed the expression of genes in the GABA signalling system — a mechanism for the calming effect | 2016 |
| Kasian et al.4 | Rat (chronic stress) | Enhanced diazepam's anti-anxiety effect beyond diazepam alone | 2017 |
Read the human row carefully. The 2008 trial is genuinely interesting: Selank reduced anxiety about as well as a benzodiazepine comparator, but without the drowsiness and with a bit of an energising effect2. That "calm without sedation" profile is the whole reason the compound is interesting. But it is a small Russian trial, not a large independent placebo-controlled study.
The honest catch: whose evidence is it?
Plainly: Selank is an approved anxiolytic in Russia, with a real clinical track record for anxiety. But that evidence is almost entirely Russian, often in Russian-language journals, and the human trials are small by Western standards. It has not been independently replicated in large randomized controlled trials outside Russia, and long-term safety data from such trials does not exist.
The animal mechanism — GABA gene changes, serotonin and enkephalin effects, synergy with diazepam — is consistent and plausible. The human proof, held to the standard the rest of this site uses, is limited and geographically narrow.
In plain terms: approved and used for anxiety in Russia, unconfirmed by Western-trial standards.
Regulatory status
Selank is not an approved medicine in the United States or the EU. In the US it appeared on the FDA's interim Category 2 list of bulk substances for compounding pharmacies — a "needs further evaluation" bin. In 2026 that status entered active review, with peptides in this group flagged for possible reclassification, so treat the exact rule as a moving snapshot. This page takes no position on sourcing and never discusses where to obtain anything.
Latest research
- The 2016 and 2017 rat studies are the freshest mechanistic work: Selank shifted GABA-system gene activity3 and amplified diazepam's calming effect in a chronic-stress model4 — both pointing at the GABA pathway.
- The 2008 Zozulia trial remains the anchor human data: anti-anxiety effect comparable to a benzodiazepine, without sedation, in generalized anxiety disorder2 — encouraging, but small and Russian.
- The live story is regulatory — the 2026 FDA review of these peptides is the most likely thing to change next. We keep this section current as new studies and decisions arrive.
The short version
Selank is a tuftsin-based peptide studied as a non-sedating anti-anxiety compound: in animals it works through the brain's calming GABA system, plus serotonin and the body's own enkephalins, and in Russia it is an approved anxiolytic. The honest limit is the evidence — small, mostly Russian, and not replicated in large Western trials — so it is best read as *clinically used in one country, unproven elsewhere*. This is an educational overview, not medical advice. Its constant companion in the Russian nootropic story is Semax; for the wider map, see what are research peptides.